Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487808 | 0.95 | ALOX5AP (0.36) | ALOX5APFEN1PDK2CYP3A4CYP2A6 | |
| SCHEMBL13487754 | 0.91 | ALOX5AP (0.36) | ALOX5APFEN1PDK2PIM1 | |
| SCHEMBL13487516 | 0.90 | PDK2 (0.35) | ALOX5APFEN1PDK2PIM1 | |
| SCHEMBL13487441 | 0.89 | PDK2 (0.39) | PDK2KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL13488127 | 0.87 | ALOX5AP (0.38) | ALOX5APFEN1PDK2PIM1 | |
| SCHEMBL13487601 | 0.87 | ALOX5AP (0.34) | ALOX5APFEN1PIM1KDM4EMEN1 | |
| SCHEMBL13487686 | 0.87 | CYP11B1 (0.36) | ALOX5APFEN1PDK2CYP3A4PIM1 | |
| SCHEMBL13487447 | 0.86 | PDK2 (0.33) | PDK2CYP3A4KDM4EMEN1ALDH1A1 | |
| SCHEMBL13487444 | 0.86 | MAP2K4 (0.40) | PDK2CYP3A4CYP2A6KDM4EALDH1A1 | |
| SCHEMBL13487042 | 0.85 | CYP3A4 (0.35) | ALOX5APFEN1PDK2CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | ALOX5AP 230/4885FEN1 1389/4885PDK2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.